GAITOX

Treatment tested

• Onabotulinumtoxina

  Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor

Other measures (4)

Inclusion Criteria: * MS patients aged over 18 years * with gait problems related to spasticity of the triceps surae, * walking 10 m in less than a minute, * with or without technical assistance, * with an EDSS of 6.5 or less * triceps surae spasticity of between 1 and 3 on the Modified Ashworth Scale. Exclusion Criteria: * Comprehension problems preventing the patient from expressing his/her free and informed consent to the study. * Intolerance to botulinum toxin; * botulinum toxin injection in the previous three months.

Introduction/Objectives: In this observational study, we assessed the benefit following an injection of 200 international units (IU) of incobotulinum toxinA in patients with multiple sclerosis (MS) with spasticity of the triceps surae (TS) at 6 weeks (peak efficacy of toxin) and at 3 months (cancellation of efficacy). Methods: This study enrolled all MS patients willing to participate with Expanded Disability Status Scale (EDSS) scores of less than 6, who required toxin for management of focal spasticity of the TS. Treatment consisted of 200 IU of incobotulinum toxinA injected into the TS. Outcome measures were assessed before injection, at 6 weeks and 3 months post-injection, using the Goal Attainment Scale (GAS), Twelve Item MS Walking (MSWS-12) Scale, Timed Up and Go (TUG) Test, 6 Minute Walk Test (6MWT). Spatiotemporal gait data was obtained by GAITRite.